Andrew Batey of Side Door Ventures joins Sunny Ray to explain how a fund that has made roughly 200 investments stays organized while seeing eight to 10,000 companies a year. He describes building focused funds that share centralized deal flow, including a Michigan fund centered on advanced materials, advanced compute and manufacturing, each with its own investment committee. Batey argues that fast, candid rejections turn founders into sources of future deal flow. He recounts early checks into K2 Space, Varda and EtherFi, and explains how the firm tracks returns two ways, one strict and one that includes SAFEs and tokens, with IRR averaging in the 40s across 14 vehicles. The conversation covers his shift toward biotech, robotics and hardware AI as AI compresses development timelines, plus the "die admirably" advice he gives founders, which he took from an investor in his own founder days. He closes with his view on machine economies, saying no one can predict which payment rail wins, though transaction costs should fall.
A fund that sees 10,000 companies a year says no fast, explains why, and tells founders to die admirably.
You say you go deep, not wide. How does that work across your funds?
We go deep within segments. Each fund is a product with a specific focus, like our Michigan fund on advanced materials, advanced compute and manufacturing, so they don't cannibalize each other. We centralize deal flow and send each company to the right fund, and every fund has its own investment committee making its own decisions.
How do you handle the flood of first meetings, and what do you tell founders you pass on?
We see eight to 10,000 companies a year, so the hard part is getting to a fast no. I tell founders exactly why, like I don't believe your market sizing. We're wrong 75 to 80 percent of the time anyway, and the founders we've been direct with have often become our best sources of deal flow.
How do you count your returns, and what is the number?
We run two numbers. One follows strict industry valuation policy, marking equity investments and reevaluating every 18 months. The other reflects what we believe the value is, including SAFEs, tokens and digital assets we could sell for cash. Across all 14 vehicles, IRR has averaged somewhere in the 40s percent.
Which area looks most mispriced right now?
Biotech. When I started investing in defense and space, people thought I was crazy, and now everyone is in a feeding frenzy on AI and defense. I think AI compresses biotech timelines, maybe from 15 years to six or eight, and some countries are cutting red tape for trials. We still do defense selectively, but we're moving into biotech, robotics and hardware.
What do you need to see in a founder that a deck never shows?
Seeing thousands of companies lets me stack rank, so I can tell when a deal is 25th out of a hundred. We validate the problem through our commercial network and aim to reach an answer within 14 days. After that, a lot of it is gut instinct about whether this person has it.
What is the 'die admirably' advice you give founders?
An investor gave me a check when I was a founder and told me to die admirably, since my odds were under one percent. It freed me. Now I tell founders we've already modeled most of them failing, so go for broke and give it your all rather than playing it safe.
Will machines need their own form of money?
I think one payment rail will win, but nobody can predict which one. There will be some exchange of value, whether tokens, compute exchange or even bartering. Computers will find the most efficient route, maybe not on a single chain. I do think transaction costs will decline, and different kinds of value may be exchanged.
Building something daring? Sunny talks to founders like this every day. Fifteen minutes to see if your story belongs on the stage.
Claim your pre-interviewSend a founder here and we will know it was you.
One email a week. The best ideas from the show, read through bitcoin, AI and robots, and what founders should do about them.